METHODS:
Topical tacrolimus (0.1%) was used to treat mice that underwent tail superficial/deep lymphatic ablation or popliteal lymph node dissection (PLND). To test the hypothesis that this therapy prevents development of lymphedema, mice were treated after a short delay following surgery (2 weeks). Other animals were treated once lymphedema was established (6 weeks postop) to test the hypothesis that topical tacrolimus can be used to treat established lymphedema. Outcomes including fibroadipose tissue deposition, limb volumes, inflammation, lymphangiogenesis, lymphatic transport and pumping capacity were then measured.
RESULTS:
Treatment with topical tacrolimus did not result in significant systemic absorption or immunosuppression.
However, this treatment markedly decreased swelling, soft tissue thickness, and fibrosis in the tail model of lymphedema. In addition, topical tacrolimus treatment significantly decreased T cell infiltration. Preventative treatment eliminated more than 95% of lymphedema-associated swelling while late treatment reduced swelling by more than 70%. Technetium 99 lymphoscintigraphy showed that preventative treatment resulted in a 5-fold increase in interstitial fluid transport to regional lymph nodes. This increased transport capacity corresponded to a more than 2 fold increase in collecting lymphatic pumping capacity as measured by near infra-red lymphangiography. Interestingly, tacrolimus application significantly increased formation of collateral superficial lymphatics and increased inflammatory lymphangiogenesis in 2 other in vivo lymphangiogenesis assays. We observed more collateral lymphatic vessels in both the tail and the PLND models.
CONCLUSION:
Treatment with topical tacrolimus markedly decreased chronic T cell inflammation, significantly improved formation of lymphatic collaterals, and decreased tissue fibrosis. These changes were associated with significant decreases in lymphedema and improved lymphatic function. These results have significant implications for the treatment of lymphedema because there is currently no effective pharmacologic treatment for this chronic disease.
is the pathologic formation of endochondral bone in soft tissue commonly occurring after severe trauma. HO is a SMAD-signaling dependent process typically occurring in response to an acute inflammatory insult. Traditionally targeted therapeutics for treatment of HO have focused on mesenchymal cell progenitors. However, macrophages which are integral orchestrators of the initial inflammatory response and are primary agents of cytokine secretion in wound regeneration, have received little attention. Here we identify a role of macrophage production of TGFβ in HO and demonstrate a role for macrophage targeted therapies in the treatment and prevention of this debilitating condition.
METHODS:
Wild type and macrophage-specific TGFβ knockout mice (LysM-cre/Tgfb fl/fl ) mice underwent hindlimb Achilles' tendon transection and dorsal 30% TBSA burn. Mice were euthanized at 2, 5, and 12days, and 3 and 9 weeks after injury. A concurrent cohort of wild type animals was treated with i.v. trabectedin (0.15 mg/kg), a macrophage-depleting agent, administered twice or vehicle control to assess the effect on HO. The tenotomy site of wild-type mice harvested at 2-, 5-, and 12-days were digested to a single-cell suspension, stained with antibodies against macrophage markers (Ly6G, Ly6C, F4/80, CD11b) and TGF-β for flow cytometric analysis. MicroCT images were obtained at 9 weeks after injury among wild type and TGFβ knockout mice, and among trabectedin and control-treated mice. In vitro and in vivo studies were performed to validate a novel PLGA microparticle system with preferential uptake by macrophages.
RESULTS:
Flow cytometry of tissue from wild type mice demonstrated enrichment of TGFβ in F4/80+ macrophages at all time-points with macrophages present as the dominant inflammatory population by 12-days post-injury (76%; p<0.05). LysM-cre/TGFβ mice similarly demonstrated a significant reduction in tHO volume vs. wild type controls (7.49 v. 1.25 mm3, p=.007). Macrophage depletion via trabectedin led to a 12.9-fold decrease in tHO volume when compared with control-treated mice (p<0.008). Histologic analysis at 3-weeks confirmed diminished cartilage presence in both mutant and trabectedin-treated mice when compared with respective controls. Finally, the PLGA microparticle demonstrated preferential uptake by macrophages both in vitro and in the wound site in vivo.
CONCLUSION:
We demonstrate that TGFβ is present in macrophages at the tenotomy site and that these macrophages comprise an increasingly large portion of the inflammatory infiltrate through 12-days post-injury. Global inhibition via trabectedin therapy is effective in preventing tHO. Importantly, genetic loss of TGFβ among macrophages was sufficient to significantly reduce HO. Our findings are strengthened by the development of a novel microparticle which exhibits preferential uptake by macrophages for drug delivery.
